Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Editorial entitled "Understanding Parkinson Disease" published
in the January 27, 1999, issue of THE JOURNAL (1999;281:376-378), selegiline
was identified as an MAO type A inhibitor rather than a type B inhibitor.
On page 377, the sentence should have read, "Selegiline is a monoamine oxidase
type B inhibitor that limits the formation of free radicals derived from oxidation
of dopamine, and application of this agent in clinical trials suggests an
effect on disease progression consistent with a neuroprotective action.23-25"
Author Omitted. JAMA. 1999;282(1):29. doi:10.1001/jama.282.1.29
Create a personal account or sign in to: